Last updated: 8 September 2023 at 5:01pm EST

J. Jeffrey Goater Net Worth




The estimated Net Worth of Jeff Goater is at least $4.47 Million dollars as of 21 July 2021. Mr. Goater owns over 127,778 units of Surface Oncology Inc stock worth over $138,268 and over the last 9 years he sold SURF stock worth over $2,694,446. In addition, he makes $1,642,260 as President, Chief Executive Officer, and Director at Surface Oncology Inc.

Mr. Goater SURF stock SEC Form 4 insiders trading

J has made over 6 trades of the Surface Oncology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 127,778 units of SURF stock worth $779,446 on 21 July 2021.

The largest trade he's ever made was selling 250,000 units of Surface Oncology Inc stock on 10 June 2021 worth over $1,915,000. On average, J trades about 20,673 units every 28 days since 2016. As of 21 July 2021 he still owns at least 129,222 units of Surface Oncology Inc stock.

You can see the complete history of Mr. Goater stock trades at the bottom of the page.





J. Jeffrey Goater biography

J. Jeffrey Goater is President, Chief Executive Officer, Director of the Company. Mr. Goater previously served as our Secretary from February 2017 to September 2018, and as our Chief Business Officer from February 2017 to February 2018. Prior to Surface, Mr. Goater served as the Chief Financial Officer and held other senior business and finance positions at Voyager Therapeutics, Inc., from September 2013 to December 2016. Prior to that, he served as Vice President of Business Development at Synageva BioPharma Corp. (now Alexion Pharmaceuticals, Inc.), from April 2013 to July 2013, and prior to that, he worked as an investment banker at Evercore Partners Inc. (now Evercore Inc.), from April 2008 to April 2013, most recently as Managing Director. Prior to that, Mr. Goater worked as an equity research analyst at Cowen and Company, LLC, covering the biopharmaceutical sector, from August 2004 to March 2008. He also currently serves on the board of directors of Vaccinex, Inc., a publicly traded biotechnology company. Mr. Goater received a B.A. in Biology, an M.S. in Pathology, an M.S. in Microbiology and Immunology, and an M.B.A., all from the University of Rochester. Our Board of Directors believes that Mr. Goater’s experience as our Chief Executive Officer, as well as his experience in the life science industry, qualifies him to serve on our Board of Directors.

What is the salary of J Goater?

As the President, Chief Executive Officer, and Director of Surface Oncology Inc, the total compensation of J Goater at Surface Oncology Inc is $1,642,260. There are no executives at Surface Oncology Inc getting paid more.



How old is J Goater?

J Goater is 44, he's been the President, Chief Executive Officer, and Director of Surface Oncology Inc since 2018. There are 16 older and no younger executives at Surface Oncology Inc. The oldest executive at Surface Oncology Inc is Elliott Sigal, 68, who is the Independent Director.

What's J Goater's mailing address?

Jeff's mailing address filed with the SEC is C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Surface Oncology Inc

Over the last 6 years, insiders at Surface Oncology Inc have traded over $69,198,912 worth of Surface Oncology Inc stock and bought 2,836,996 units worth $42,496,090 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Surface Oncology Inc executives and independent directors trade stock every 37 days with the average trade being worth of $156,856. The most recent stock trade was executed by Alison Oneill on 1 August 2023, trading 7,042 units of SURF stock currently worth $6,619.



What does Surface Oncology Inc do?

surface oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. the company’s scientific founders and sab are comprised of world‐leading immunologists and cancer researchers, including co‐chairs sasha rudensky (memorial sloan kettering) and arlene sharpe (harvard/dfci). they are joined on the sab by christopher hunter and john wherry (university of pennsylvania), carla rothlin (yale university), elliott sigal, and john stagg (university of montreal). surface oncology recently completed a $35 million series a financing round with a-list backers. atlas venture, which seeded the company in 2014, led the round, joined by new enterprise associates, fidelity biosciences, lilly ($lly) ventures, amgen ($amgn) ventures, novartis ($nvs) institute for biomedical research, and elliott sigal, the former head of r&d at bristol-myers. for more information, visit ww



What does Surface Oncology Inc's logo look like?

Surface Oncology Inc logo

Complete history of Mr. Goater stock trades at Voyager Therapeutics Inc, Surface Oncology Inc, Vaccinex Inc, and ContextLogic Inc

Date
#
Company
Insider
Trans.
Transaction
Shares Price per share Total value Shares after Source
21 Jul 2021 Jeff Goater
Director
Sale 127,778 $6.10 $779,446
21 Jul 2021
129,222
10 Jun 2021 Jeff Goater
Director
Sale 250,000 $7.66 $1,915,000
10 Jun 2021
257,000
8 Feb 2021 Jeff Goater
Director
Option 2,500 $3.18 $7,950
8 Feb 2021
264,500
1 Feb 2021 Jeff Goater
Director
Option 2,500 $3.18 $7,950
1 Feb 2021
264,500
19 Jan 2021 Jeff Goater
Director
Option 5,000 $3.18 $15,900
19 Jan 2021
267,000
5 Feb 2020 Jeff Goater
Director
Buy 5,000 $3.23 $16,150
5 Feb 2020
262,000


Surface Oncology Inc executives and stock owners

Surface Oncology Inc executives and other stock owners filed with the SEC include: